Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2025-05-22 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is an intimation letter to stock exchanges about a forthcoming Board Meeting scheduled for May 30, 2025. It outlines the agenda items including approval of audited financial results for the quarter/year ended March 31, 2025, dividend recommendation, and appointment of auditors. The document does not contain actual financial data or results but is a notice of the meeting where such matters will be considered. It is a regulatory announcement under SEBI Listing Obligations and Disclosure Requirements. The document length is short (2504 characters) and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and intimation to exchanges about board meeting and upcoming financial results disclosure.
2025-05-22 English
Updates
Regulatory Filings Classification · 95% confidence The document is a corrigendum to a previously filed outcome of a Board Meeting, specifically correcting the number of equity shares allotted. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events including board meeting outcomes. The document is short (2068 characters) and serves as an update or correction to a prior announcement rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2025-04-25 English
Outcome of Board Meeting
Capital/Financing Update Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) reporting the outcome of a Board of Directors meeting held on April 24, 2025. The content details the allotment of equity shares and fully convertible warrants, including the number of shares/warrants allotted, the issue price, and the resulting increase in paid-up equity share capital. This is a clear update on the company's capital structure changes. The document is short (3,584 characters) and serves as an announcement of these allotments rather than a detailed financial report or analysis. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-04-25 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board of Directors meeting. It details the allotment of equity shares and convertible warrants, specifying the number of shares/warrants allotted, the issue price, and the categories of allottees. The document also states the consequent increase in the paid-up equity share capital of the company. There is no financial statement or detailed financial analysis present, nor is this a report or presentation. The content clearly relates to changes in the company's capital structure through share allotment. Therefore, this document fits the category of 'Capital/Financing Update' (CAP). The document length is 3560 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2025-04-25 English
Outcome of Board Meeting
Capital/Financing Update Classification · 100% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board of Directors meeting. It details the allotment of equity shares and convertible warrants, specifying the number of shares/warrants allotted, the issue price, and the categories of allottees. The document also states the consequent increase in the company's paid-up equity share capital. There is no financial statement or detailed financial analysis present, only an announcement of capital raising activities approved by the board. The document length is 3538 characters, which is relatively short and consistent with an announcement rather than a full report. The content clearly relates to capital structure changes and fundraising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-04-24 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-04-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.